Related references
Note: Only part of the references are listed.The SR protein family of splicing factors: master regulators of gene expression
Jennifer C. Long et al.
BIOCHEMICAL JOURNAL (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia
Victoria L. Bills et al.
CLINICAL SCIENCE (2009)
Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Benjamin Purow
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2009)
Vascular permeability, vascular hyperpermeability and angiogenesis
Janice A. Nagy et al.
ANGIOGENESIS (2008)
5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells
E. Miller-Kasprzak et al.
BIOMEDICINE & PHARMACOTHERAPY (2008)
VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma:: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
A. H. R. Varey et al.
BRITISH JOURNAL OF CANCER (2008)
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
E. S. Rennel et al.
BRITISH JOURNAL OF CANCER (2008)
VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
G. Thurston et al.
BRITISH JOURNAL OF CANCER (2008)
Multiple alternative splicing markers for ovarian cancer
Roscoe Klinck et al.
CANCER RESEARCH (2008)
Identification of Alternative Splicing Markers for Breast Cancer
Julian P. Venables et al.
CANCER RESEARCH (2008)
Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity
Harukiyo Kawamura et al.
CANCER RESEARCH (2008)
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice
Emma S. Rennel et al.
EUROPEAN JOURNAL OF CANCER (2008)
Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF(165)b
Yan Qiu et al.
FASEB JOURNAL (2008)
Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A
Jun-ichiro Yomoda et al.
GENES TO CELLS (2008)
p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors:: VEGF165b downregulation as a marker of poor prognosis
Raquel Diaz et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
Dawid G. Nowak et al.
JOURNAL OF CELL SCIENCE (2008)
Ordered multi-site phosphorylation of the splicing factor ASF/SF2 by SRPK1
Chen-Ting Ma et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 alpha
Mei Y. Koh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The Alternatively Spliced Anti-Angiogenic Family of VEGF Isoforms VEGF(xxx)b in Human Kidney Development
Heather S. Bevan et al.
NEPHRON PHYSIOLOGY (2008)
Vascular endothelial growth factor in eye disease
J. S. Penn et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Autocrine VEGF signaling is required for vascular homeostasis
Sunyoung Lee et al.
CELL (2007)
Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma
R. O. Pritchard-Jones et al.
BRITISH JOURNAL OF CANCER (2007)
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Rotem Karni et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome
Valerie Anne Schumacher et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas
Gregory M. Hayes et al.
CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The role of VEGF and VEGFR2/Flk1 in proliferation of retinal progenitor cells in murine retinal degeneration
Koji M. Nishiguchi et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Structure of a VEGF-VEGF receptor complex determined by electron microscopy
Claudia Ruch et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
MiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia
Zhong Hua et al.
PLOS ONE (2006)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2
S. Cebe Suarez et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication
Takeshi Fukuhara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term
DO Bates et al.
CLINICAL SCIENCE (2006)
Unbalanced alternative splicing and its significance in cancer
JP Venables
BIOESSAYS (2006)
VEGFR-2 expression in brain injury:: its distribution related to brain-blood barrier markers
JV Lafuente et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma
GM Hayes et al.
CANCER RESEARCH (2006)
The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo
CA Glass et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration
MK Skold et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Alternative splicing: A new drug target of the post-genome era
M Hagiwara
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor
RM Perrin et al.
DIABETOLOGIA (2005)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing
LK Zerbe et al.
MOLECULAR CARCINOGENESIS (2004)
VEGF165b, an inhibitory vascular endothelial growth factor splice variant:: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression
J Woolard et al.
CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors.: VEGF D and flt-4tΔ773-1081 overexpression is diagnostic for sentinel lymph node metastasis
ME Stearns et al.
LABORATORY INVESTIGATION (2004)
Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements
IG Bruno et al.
HUMAN MOLECULAR GENETICS (2004)
Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays
JM Johnson et al.
SCIENCE (2003)
Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis
M De Bandt et al.
JOURNAL OF IMMUNOLOGY (2003)
Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss
B Modrek et al.
NATURE GENETICS (2003)
Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes
RR Foster et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia
K Koga et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
The 17q23 amplicon and breast cancer
CS Sinclair et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfimction, hypertension, and proteinuria in preeclampsia
SE Maynard et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
V Eremina et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor
I Casella et al.
BLOOD (2003)
Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo
KL Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy
SM Vickers et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2002)
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
D Lyden et al.
NATURE MEDICINE (2001)
Share Paper
